We are live on ! Find out more
PDSB icon

PDS Biotechnology

21 hedge funds and large institutions have $2.76M invested in PDS Biotechnology in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

30% more capital invested

Capital invested by funds: $2.12M → $2.76M (+$638K)

24% more funds holding

Funds holding: 1721 (+4)

3.53% more ownership

Funds ownership: 5.37%8.91% (+3.5%)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
21
Holders Change
+4
Holders Change %
+23.53%
% of All Funds
0.46%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
3
Reduced
5
Closed
3
Calls
Puts
Net Calls
Net Calls Change

PDSB Hedge Fund Activity: Q2 2019 in Review

21 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2019, worth a combined $2.76M — up 30% from $2.12M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PDSB positions and 3 closed out — a net gain of 4 holders — while 3 added to existing stakes and 5 trimmed.

The largest buyer was New Leaf Venture Partners, opening a new position worth an estimated $767K. The largest seller was D.E. Shaw & Co, cutting an estimated $165K.

  • 21 institutional investors held PDS Biotechnology (PDSB) as of Q2 2019, up from 17 in Q1 2019.
  • Funds reported $2.76M of PDS Biotechnology stock for Q2 2019, up 30% quarter-over-quarter.
  • 7 funds opened new PDS Biotechnology positions in Q2 2019 and 3 closed out, a net change of +4 holders.
  • The largest PDS Biotechnology buyer in Q2 2019 was New Leaf Venture Partners, an estimated $767K added.
  • The largest PDS Biotechnology seller in Q2 2019 was D.E. Shaw & Co, an estimated $165K sold.

Based on aggregated 13F filings for Q2 2019.